Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar Advisory Committees Will Focus Less On Clinical Data

Executive Summary

FDA wants panels to look more closely at analytics in lesson learned from Zarxio meeting.


Related Content

Mylan's Herceptin Advisory Committee May Be First Bumpy One For A Biosimilar
Biosimilar Advisory Committee Reviews: Necessity Or Nuisance?
Biosimilar Advisory Committee Features Actual Debate About Biosimilarity
FDA’s Inaugural Biosimilar Review Bumpier Than First Appeared
Biosimilar Podium Promotion: FDA Emphasizes Advantages Of Abbreviated Pathway


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts